Loading asset research
Editas Medicine Inc. Common Stock
EDITNasdaq · USD · StocksQuote as of · Exchange session not verified$2.72
+2.64%
Today
EDIT
Loading 1D prices…
Market cap
$414.7M
Volume
2.5M
52w high
$4.5452w low
$1.66Company profile
Editas Medicine Inc. Common Stock
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Cambridge, MA, United States
Employees
87
Fiscal year end
1231
CIK
1650664
Session & valuation
Open$2.68
Previous close$2.65
Day high$2.72
Day low$2.62
30-day avg. volume2.4M
Outstanding shares153.6M
Diluted EPS-$1.80
Latest annual period
P/E (trailing)-1.51
P/E (forward)-3.59
Price / book3.94
Beta2.09
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| CCCCC4 Therapeutics Inc. Common Stock | $431.8M | $35.9M | -292.08% | -$1.27 | +3.24% | Buy |
| FENCFennec Pharmaceuticals Inc. Common Stock | $384.3M | $44.6M | -21820.26% | -$0.34 | -3.01% | Buy |
| KYTXKyverna Therapeutics Inc. Common Stock | $449M | $0.00 | — | -$3.64 | -1.22% | Buy |
| DNAGinkgo Bioworks Holdings Inc. Class A Common Stock | $454.5M | $170.2M | -0.18% | -$5.64 | -0.59% | Sell |
| CABACabaletta Bio Inc. Common Stock | $462.9M | $0.00 | — | -$2.10 | -0.18% | Buy |